Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis
Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis
MG may be neonatal, congenital, or autoimmune. Neonatal MG arises from transplacental
 transfer of ACh receptor antibodies from a mother with autoimmune MG to the fetus. Neonatal
 MG resolves with post delivery clearance of maternal antibodies. Congenital MG results from a
 genetic defect in the ACh receptor. Patients with congenital MG do not have ACh receptor
 antibodies. Both neonatal and congenital MG are excluded from this study. Autoimmune MG,
 which is the most common form of MG, affects approximately 25,000 Americans. Like most
 autoimmune diseases, it is associated with particular HLA genotypes, has a female
 predominance, and environmental factors involved in breaking tolerance to the ACh receptor
 are unknown. Patients with refractory and severe autoimmune MG will be considered candidates
 for this study.

 The purpose of this study is to assess the toxicity/feasibility (phase I) of autologous
 hematopoietic stem cell transplantation for refractory myasthenia gravis.
There will be no randomization in this study. All subjects who are determined to be eligible
 for the study treatment will receive high dose cyclophosphamide and ATG followed by infusion
 of autologous peripheral blood stem cells. The procedures the subject will undergo are as
 follows:

 1. Physician visit to determine potential eligibility for the study. Subjects will be
 evaluated by a transplant physician and a neurologist. They will have a complete
 physical examination and will provide a full medical history at these visits. The study
 will be described in detail by the transplant physician and nurse and the consent form
 will be provided to be taken home to read.

 2. Insurance verification. Subjects who remain interested in pursuing the study treatment
 and who have refractory myasthenia gravis will proceed to the insurance verification
 phase. Third party payment or self-pay must be verified before subjects can proceed.

 3. Consent form. Prior to proceeding, the appropriate signatures will be obtained on the
 consent form. Subjects will be given an opportunity to ask further questions of the
 attending physician and transplant nurse prior to signing the consent form.

 4. Pre-transplant testing. To determine final eligibility for the study, subjects will
 undergo a series of tests/procedures. These include: CXR; electrocardiogram; MUGA or
 echocardiogram; pulmonary function test; CT scan of the sinuses; CT scan of the chest to
 r/o thymoma; dental examination; urinalysis; and blood testing to include CBC,
 chemistries, liver and kidney function tests, coagulation studies, viral studies and,
 for females, a pregnancy test. All pre-transplant testing is routine medical testing
 done to verify diagnosis and to insure adequate organ function and absence of viral
 illnesses which would preclude a safe transplant course.

 5. Autologous peripheral blood stem cell collection. Subjects who are proceeding to
 transplant will undergo a routine procedure for the mobilization and collection of
 peripheral blood stem cells. This includes the administration of IV cyclophosphamide,
 given as an inpatient requiring an overnight stay, followed by the subcutaneous
 administration of G-CSF, to be self-administered as an outpatient. Approximately ten
 days after the administration of IV cyclophosphamide, the peripheral blood stem cells
 will be collected as an outpatient in the Blood Center. A pheresis catheter will be
 placed for this purpose on the first day of leukopheresis. Leukopheresis will be
 continued on a daily basis until an adequate number of peripheral blood stem cells have
 been collected (a maximum of four leukophereses may be performed). G-CSF will continue
 to be administered until leukopheresis is completed. The pheresis catheter will be
 discontinued when stem cell harvesting is completed. Processed cells will be frozen and
 stored until they are reinfused after the conditioning regimen.

 6. PICC line placement. Subjects will have a double lumen PICC line placed prior to the
 administration of study treatment for the administration of chemotherapy, IV fluids,
 blood products and the withdrawal of blood samples. The placement of a PICC line is a
 routine medical procedure.

 7. Study treatment. Subjects will undergo conditioning which will include four days of
 intravenous high dose cyclophosphamide and three days of intravenous anti-thymocyte
 globulin (ATG). Both cyclophosphamide and ATG are common immune suppressive agents. The
 previously collected peripheral blood stem cells will be reinfused following the
 completion of the conditioning regimen.

 8. Post-treatment follow-up. Subjects will have a history and physical by the transplant
 physician and neurologist at 3 months, 6 months, 12 months, and yearly for 5 years. In
 addition, routine urinalysis and blood testing will be performed at these same intervals
 to include CBC, chemistries, kidney and liver function tests.
Inclusion Criteria (Patients must fulfill all of the following)

 1. Established diagnosis of myasthenia gravis defined as clinical evidence of muscle
 weakness and fatigue ability and supported, an abnormal EMG-NCV repetitive nerve
 stimulation (or single-fiber EMG) or Lambert-Eaton Myasthenic Syndrome without
 evidence of malignancy.

 2. Ages 15-65 years.

 3. Positive antibody preferred (anti-AchR, MuSK, voltage gated calcium channel,
 anti-striational).

 4. Failure of thymectomy (except for Lambert-Eaton Myasthenic Syndrome).

 5. Failure anticholinesterase therapy, corticosteroids, and at least two of the
 following: azathioprine, cyclosporin, CellCept, cyclophosphamide, plasma exchange, or
 IVIG. Failure is defined as at least 6 months of the above drug therapy and an
 Osserman score of IIB, III, or IV and not clinically improving.

 And at least one of the following:

 1. History of myasthenia crises (requiring mechanical ventilation) despite thymectomy and
 immunosuppressive therapy.

 2. Hospitalized or on ventilator support for myasthenia gravis within the last 18 months
 despite thymectomy and immunosuppressive therapy.

 3. Inability to maintain nutrition due to muscle weakness.

 4. A Karnofsky performance status of 70% or less (may or may not be able to care for
 self, but unable to carry on normal activity or unable to do active work).

 Exclusion Criteria

 1. Significant end organ damage such as:

 1. LVEF <40% or deterioration of LVEF during exercise test on MUGA or
 echocardiogram.

 2. Untreated life-threatening arrhythmia, active ischemic heart disease or heart
 failure.

 3. DLCO < 40% of predicted value.

 4. Serum creatinine > 2.5 mg/dl.

 5. Liver cirrhosis, transaminases >3x of normal limits, or bilirubin >2.0 unless due
 to Gilberts disease.

 2. HIV positive.

 3. Uncontrolled diabetes mellitus, or any other illness that in the opinion of the
 investigators would jeopardize the ability of the patient to tolerate aggressive
 treatment.

 4. Prior history of malignancy except localized basal cell or squamous skin cancer. Other
 malignancies for which the patient is judged to be cured by local surgical therapy,
 such as (but not limited to) head and neck cancer, or stage I or II breast cancer,
 will be considered on an individual basis.

 5. Positive pregnancy test, inability or unable to pursue effective means of birth
 control, failure to willingly accept or comprehend irreversible sterility as a side
 effect of therapy.

 6. Psychiatric illness or mental deficiency making compliance with treatment or informed
 consent impossible.

 7. Inability to give informed consent

 8. Congenital myasthenia gravis

 9. Neonatal myasthenia gravis

 10. Osserman grade 1 or 2

 11. Pure red cell aplasia

 12. Any patient on insulin